PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 5 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
Beaucarnea recurvata leaf extract (BRLE) was tested in an acetic acid-induced ulcerative colitis rat model at doses of 100, 200, and 400 mg/kg to evaluate clinical parameters, histopathology, oxidative stress markers, inflammatory cytokines, and protein expression [PMID:41465478].
Evidence summary
PubMed sources
- 1.PMID: 21440920 (2011) — Steroidal saponins from the leaves of Beaucarnea recurvata. · Phytochemistry
- 2.PMID: 41465478 (2025) — Therapeutic Potential of Beaucarnea recurvata Leaf Extract Against Ulcerative Colitis: Integrating Phytochemical Profiling, Network Pharmacology, and Experimental Validation. · International journal of molecular sciences
- 3.PMID: 32821215 (2020) — Additions to Phaeosphaeriaceae (Pleosporales): Elongaticollum gen. nov., Ophiosphaerella taiwanensis sp. nov., Phaeosphaeriopsis beaucarneae sp. nov. and a new host record of Neosetophoma poaceicola from Musaceae. · MycoKeys